Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 519-533 , September 2006

Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders

  • Bart Scott (Member, Fred Hutchinson Cancer Research CenterProfessor of Medicine, University of Washington, Seattle, WA)
    • ,
  • H. Joachim Deeg (Research Associate, Fred Hutchinson Cancer Research CenterActing Instructor, University of Washington, Seattle, WA)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 288 1024; Fax: +1 206 667 6124.

References 

  1. Greenberg PL. Myelodysplastic syndrome. In:  Hoffman R,  Benz EJ,  Shattil SJ,  Furie B,  Cohen HJ,  Silberstein LE,  McGlave P editor. Hematology: Basic Principles and Practice. New York: Churchill Livingstone; 2000;p. 1106–1129
  2. Sanz GF, Sanz MA, Vallespì T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395–408
  3. Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) co-operative group: proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  4. Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting—Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood Feb 1; 91(3): 1100). Blood. 1997;89:2079–2088
  6. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004
  7. Rozman C, Giralt M, Feliu E, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658–2663
  8. Barosi G, Berzuini C, Liberato LN, et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397–401
  9. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013–1018
  10. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849
  11. Thomas ED. Bone marrow transplantation: a review. Semin Hematol. 1999;36(supplement 7):95–103
  12. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585
  13. Sorror ML, Maris MB, Storb RF, et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biol Blood Marrow Transplant. 2005;11(supplement 1):23–24[#67, 2005 (abstract)]
  14. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326–2331
  15. Scott BL, Storer B, Loken M, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:65–73
  16. de Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol. 1990;74:151–155
  17. Appelbaum FR, Barrall J, Storb R, et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med. 1990;112:590–597
  18. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220–226
  19. Anderson JE, Anasetti C, Appelbaum FR, et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 1996;93:59–67
  20. Demuynck H, Verhoef GE, Zachee P, et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant. 1996;17:745–751
  21. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358–365
  22. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910–1917
  23. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic leukemia working party of the european group for blood and marrow transplantation. Bone Marrow Transplant. 1998;21:255–261
  24. Arnold R, de Witte T, van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey, european blood and marrow transplantation group. Bone Marrow Transplant. 1998;21:1213–1216
  25. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55–66 years of age. Blood. 2000;95:1188–1194
  26. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the chronic Leukaemia working party of the european group for blood and marrow transplantation (EBMT). Br J Haematol. 2000;110:620–630
  27. de Witte T, Pikkemaat F, Hermans J, et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia. 2001;15:1878–1884
  28. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national marrow donor program. Blood. 2002;99:1943–1951
  29. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  30. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant. 2002;8:161–169
  31. Nevill TJ, Shepherd JD, Reece DE, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992;10:445–450
  32. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51–58
  33. Copelan EA, Penza SL, Elder PJ, et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant. 2000;25:1219–1222
  34. Guardiola P, Runde V, Bacigalupo A, et al. Subcommittee for Myelodysplastic syndromes of the chronic Leukaemia working group of the european blood and marrow transplantation group: retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2002;99:4370–4378
  35. Longmore G, Guinan EC, Weinstein HJ, et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990;8:1707–1714
  36. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 1993;81:2194–2199
  37. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 1995;13:2973–2979
  38. Mattijssen V, Schattenberg A, Schaap N, et al. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant. 1997;19:791–794
  39. Okamoto S, Takahashi S, Wakui M, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol. 1999;104:569–573
  40. Hsu C, Lin MT, Tang JL, et al. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. J Formos Med Assoc. 1999;98:157–164
  41. Anderson JE, Appelbaum FR, Schoch G, et al. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biol Blood Marrow Transplant. 2001;7:163–170
  42. Bibawi S, Abi-Said D, Fayad L, et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001;67:227–233
  43. Bornhäuser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–826
  44. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  45. Singhal S, Powles R, Treleaven J, et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant. 1995;16:743–746
  46. Guardiola P, Esperou H, Cazals-Hatem D, et al. French society of BMT: allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol. 1997;98:1004–1009
  47. Anderson JE, Sale G, Appelbaum FR, et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997;98:1010–1016
  48. Przepiorka D, Giralt S, Khouri I, et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases (Review). Am J Hematol. 1998;57:24–28
  49. van Besien K, Deeg HJ. Hemopoietic stem cell transplantation for myelofibrosis (Review). Semin Oncol; in press.
  50. Guardiola P, Anderson JE, Bandini G, et al. Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del midollo osseo, and Fred Hutchinson cancer research center collaborative study. Blood. 1999;93:2831–2838
  51. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–3918
  52. Platzbecker U, Gooley T, Anasetti C, et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma. 2002;43:1409–1414
  53. Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol. 2000;110:217–222
  54. Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic Leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol. 2002;118:67–73
  55. de Witte T, van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood. 1997;90:3853–3857
  56. Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia. 1999;13:524–529
  57. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586–593
  58. Carella AM, Champlin R, Slavin S, et al. Mini-allografts: ongoing trials in humans (Editorial). Bone Marrow Transplant. 2000;25:345–350
  59. Kroger N, Schetelig J, Zabelina T, et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2001;28:643–647
  60. Martino R, Caballero MD, Simón JA, et al. AML and alloPBSCT subcommittees of the Spanish group for hematopoietic transplantation: evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243–2245
  61. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood. 2004;104:1616–1623
  62. Stuart MJ, Cao TM, Sandmaier BM, et al. Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood. 2003;102(Part 1):185a;[#644, 2003 (abstract)]
  63. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255–2258
  64. Rondelli D, Barosi G, Bacigalupo A, et al. Non-myeloablative allogeneic HSCT in high risk patients with myelofibrosis. Blood. 2003;102:199a;[abstract]
  65. Alyea E, Kim H, Cutler C, et al. Similar outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age. Blood. 2004;104(Part 1):89a;[#300 (abstract)]
  66. Scott BL, Maris M, Sandmaier B, et al. Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multinlineage dysplasia following MDS (tAML). Blood. 2004;104(Part 1):638a;[#2320 (abstract)]
  67. Benesch M, Deeg HJ. Hemopoietic cell transplantation for myelodysplastic syndromes. Curr Hematol Rep. 2003;2:209–216
  68. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 2003;102:394–403
  69. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030

PII: S1521-6926(05)00096-4

doi: 10.1016/j.beha.2005.07.009

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 519-533 , September 2006

Article Tools

* Image Usage & Resolution